Tempus AI, Inc. Class A (TEM) Stock Price & Analysis
TEM Stock Chart & Stats
- Day’s Range
- MXN 1,352.80 - MXN 1,357.98
- 52-Week Range
- MXN 725.00 - MXN 1,679.00
- Previous Close
- MXN 1,449.62
- Volume
- 9,576
- Average Volume (3M)
- 323
- Market Cap
- MXN 247.25B
- Enterprise Value
- MXN 11.19B
- Total Cash (Recent Filing)
- MXN 815.99M
- Total Debt (Recent Filing)
- MXN 1.44B
- Price to Earnings (P/E)
- ―
- Beta
- 1.55
- Next Earnings
- Nov 02, 2026 (Est.)
- EPS Estimate
- -1.65
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Data-platform Expansion
Large, multi-year data agreements validate demand for Tempus’s multimodal datasets and analytics platform. They can improve revenue visibility, deepen strategic relationships with major life-sciences customers, and reinforce the company’s position in AI-enabled drug development and real-world evidence.
Strong Revenue Growth And Gross Margin
Rapid top-line expansion combined with high gross margin indicates meaningful scale and attractive underlying unit economics. Continued growth in diagnostics and data services can generate increasing gross-profit dollars to support investment in sales capacity, technology, and broader clinical adoption.
Improving Operating Outlook
Higher revenue guidance and a targeted shift toward positive EBITDA and free cash flow signal improving operating leverage. If execution continues, stronger internal cash generation could reduce reliance on external financing and provide more flexibility to fund product development and commercial expansion.
Bears Say
High Leverage
Debt materially exceeds equity, limiting financial flexibility while the company remains in a transition toward sustained profitability. High leverage can increase financing sensitivity, constrain investment choices, and make it harder to absorb execution setbacks or fund acquisitions without additional capital.
Negative Cash Generation
The business is still consuming substantial cash rather than funding itself internally, despite recent improvement in quarterly cash use. Persistent negative operating and free cash flow can require continued financing and may limit the company’s ability to invest aggressively while also servicing debt.
Execution And Approval Dependency
Important future growth opportunities depend on regulatory approval and broader commercialization. Delays to xF or a slower sales-force rollout for MRD could defer expected revenue uplift, prolong investment needs, and make the company’s medium-term growth and cash-generation targets harder to achieve.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
What is Tempus AI, Inc. Class A’s market cap?
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
How were Tempus AI, Inc. Class A’s earnings last quarter?
Is Tempus AI, Inc. Class A overvalued?
Does Tempus AI, Inc. Class A pay dividends?
What is Tempus AI, Inc. Class A’s EPS estimate?
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
What is the TipRanks Smart Score and how is it calculated?
Tempus AI, Inc. Class A Stock Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky
- Employees
- 3,800
- Website
- www.tempus.com
- Address
- 600 West Chicago Avenue, Chicago, IL, 60654, US
Tempus AI, Inc. Class A (TEM) Earnings & Revenues
TEM Company Deck
TEM Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with 22% total revenue growth, accelerating Data and Apps momentum, major FDA and foundation-model milestones, expanding pharma partnerships, improved profitability, higher guidance, and a rapidly growing MRD opportunity. The main challenges were slower hereditary testing growth, still-negative operating cash flow, limited current MRD sales-force deployment, pending xF approval, and uncertainty around the early whole-genome ramp.
View all MX:TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 5 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 10 | 0 | 2 |











